Published

Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Cancer
Date: 2024-04-01
Source: PubMed
DOI: 10.1002/cncr.35010
PubMed: 38105655

Authors

Agrawal M Richards W Beaussant Y Shnayder S Ameli R Roddy K Stevens N Richards B Schor N Honstein H Jenkins B Bates M Thambi P

Watch author

Derived topics and classifications

psilocybin Depression Anxiety Chronic Pain Headache / Migraine Clinical Trial Observational Study Cancer Patients Safety Adverse Events Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 8 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Mindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) for cancer-related demoralization in Canada: The case for a hybrid group-based delivery model2026-12-01 Reporting practices in psilocybin-assisted therapy trials for depression: A descriptive review and temporal overview2026-07-13 PSILOCYBIN IN THE TREATMENT OF DEPRESSIVE DISORDERS: CLINICAL EVIDENCE AND ITS POTENTIAL TO ADDRESS THE GLOBAL MENTAL HEALTH CRISIS - A REVIEW2026-06-24 Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations2026-06-01 Effect of psilocybin-assisted psychotherapy on anxiety symptoms: A systematic review and meta-analysis2026-05-29 The efficacy and safety of psilocybin-assisted therapy for major depressive disorder: a meta-analytic review of clinical outcomes2026-04-21 Pilot study of psilocybin in patients with post-treatment lyme disease2026-02-25 Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder.2024-04-01

Related papers

PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical TrialClinicalTrials.gov · 2026-07-10 A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and DepressionClinicalTrials.gov · 2026-07-31 PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical TrialClinicalTrials.gov · 2026-07-10 Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)ClinicalTrials.gov · 2026-07-09 Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic EffectsClinicalTrials.gov · 2026-07-09 TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance TherapyClinicalTrials.gov · 2026-08-12 TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer SurvivorsClinicalTrials.gov · 2026-08-12 Single Dose Psilocybin for a Post-surgical Trauma Inpatient Population for Pain, Mood, and Opioid Use DisorderClinicalTrials.gov · 2026-08-06